Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention
A Global Expert Consensus Document

ABSTRACT: Outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) have improved because of advancements in equipment and techniques. With global collaboration and knowledge sharing, we have identified 7 common principles that are widely accepted as best practices for CTO-PCI.

1. Ischemic symptom improvement is the primary indication for CTO-PCI.
2. Dual coronary angiography and in-depth and structured review of the angiogram (and, if available, coronary computed tomography angiography) are key for planning and safely performing CTO-PCI.
3. Use of a microcatheter is essential for optimal guidewire manipulation and exchanges.
4. Antegrade wiring, antegrade dissection and reentry, and the retrograde approach are all complementary and necessary crossing strategies. Antegrade wiring is the most common initial technique, whereas retrograde and antegrade dissection and reentry are often required for more complex CTOs.
5. If the initially selected crossing strategy fails, efficient change to an alternative crossing technique increases the likelihood of eventual PCI success, shortens procedure time, and lowers radiation and contrast use.
6. Specific CTO-PCI expertise and volume and the availability of specialized equipment will increase the likelihood of crossing success and facilitate prevention and management of complications, such as perforation.
7. Meticulous attention to lesion preparation and stenting technique, often requiring intracoronary imaging, is required to ensure optimum stent expansion and minimize the risk of short- and long-term adverse events.

These principles have been widely adopted by experienced CTO-PCI operators and centers currently achieving high success and acceptable complication rates. Outcomes are less optimal at less experienced centers, highlighting the need for broader adoption of the aforementioned 7 guiding principles along with the development of additional simple and safe CTO crossing and revascularization strategies through ongoing research, education, and training.
Chronic total occlusions (CTOs) are completely occluded coronary arteries with Thrombolysis in Myocardial Infarction 0 flow with an estimated duration of at least 3 months. In recent years, the success rates of CTO percutaneous coronary intervention (PCI) have substantially improved, in concert with the maturation and refinement of the key indications, equipment, and techniques for recanalization of occluded coronary arteries. Global collaboration and sharing of knowledge and techniques have led to the emergence of 7 key principles for the performance of CTO-PCI that can help training, clinical practice, and education in this field (Table 1).

This document was conceived during CTO-PCI meetings in 2018 (CTO Summit, Multi-Level CTO, and EuroCTO). An initial document draft was created by a group of CTO-PCI experts from North America, Europe, and Japan. A total of 113 CTO-PCI experts from 56 countries were invited to participate, of whom 101 from 50 countries provided comments and approved the final document.

### SYMPTOM IMPROVEMENT IS THE PRIMARY INDICATION FOR CTO-PCI

Two published randomized, controlled clinical trials and several observational studies have reported symptomatic improvement after successful CTO-PCI. The EuroCTO multicenter trial (A Randomized Multicentre Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions) randomly assigned 396 patients to CTO-PCI versus optimal medical therapy alone. At 12 months, in comparison with patients randomly assigned to medical therapy only, patients randomly assigned to CTO-PCI had greater improvement in angina frequency (subscale change difference, 5.23; 95% CI, 1.75–8.71; P=0.003) and quality of life (subscale change difference, 6.62; 95% CI, 1.78–11.46; P=0.007), as assessed with the Seattle Angina Questionnaire.1 The single-center IMPACTOR-CTO trial (Impact on Inducible Myocardial Ischemia of Percutaneous Coronary Intervention versus Optimal Medical Therapy in Patients with Right Coronary Artery Chronic Total Occlusion) randomly assigned 94 patients with isolated right coronary artery CTO to CTO-PCI versus optimal medical therapy alone.2 At 12 months, in comparison with optimal medical therapy, patients undergoing CTO-PCI had a significant reduction in ischemic burden and improvement in 6-minute walk distance and quality of life as assessed by the Short Form-36 Health Survey. Such symptomatic improvement confirms results from multiple observational studies and meta-analyses.4–6 Interpretation of randomized CTO-PCI trials should take into consideration selection bias, because the most symptomatic patients were less likely to be enrolled, and crossover between arms. For example, no symptomatic benefits were observed in a third randomized trial, DECISION CTO (Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion).7 However this study enrolled patients with minimal symptoms, and crossover rates were high in both treatment arms, moving the outcomes toward the null. In addition, no sham-controlled trial has yet been performed, leaving the possibility that some of the observed benefit of CTO-PCI is mediated by the placebo effect. One such trial is underway, the SHINE-CTO trial (Sham-controlled Intervention to Improve QOL in CTOs; NCT02784418).

In observational studies, CTO-PCI relieved regional ischemia and has been associated with improved exercise capacity, increased anaerobic threshold,8 and improvement in depression.9 Viable myocardium supplied by a CTO is a persistently ischemic zone.10,11 It remains undetermined whether CTO-PCI improves other cardiovascular outcomes, such as left ventricular ejection fraction, risk for arrhythmias, and mortality. Both regional and global left ventricular function improved after successful CTO-PCI in several carefully performed observational studies12 using paired cardiac magnetic resonance imaging in patients with demonstrable viability or baseline dysfunction,13 but not in 2 randomized, controlled trials.14,15 These randomized studies, however, were performed in patients with normal mean left ventricular ejection fraction and did not examine the presence of viable dysfunctional myocardium at baseline, nor did they assess exercise-induced changes in left ventricular function. In patients with ischemic cardiomyopathy with reduced ejection fraction, the presence of ischemia and viability in the myocardium supplied by the CTO vessel should be confirmed before considering CTO revascularization. Patients with coronary CTOs who received an implantable cardioverter defibrillator for primary

### Table 1. Key Principles on the Indications and Technique of Chronic Total Occlusion Percutaneous Coronary Intervention

<table>
<thead>
<tr>
<th>Principle</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>The principal indication for CTO-PCI is to improve symptoms.</td>
</tr>
<tr>
<td>2</td>
<td>Dual coronary angiography and thorough, structured angiographic review should be performed in every case.</td>
</tr>
<tr>
<td>3</td>
<td>Use of a microcatheter is essential for guidewire support.</td>
</tr>
<tr>
<td>4</td>
<td>There are 4 CTO crossing strategies: antegrade wire escalation, antegrade dissection/reentry, retrograde wire escalation, and retrograde dissection/reentry.</td>
</tr>
<tr>
<td>5</td>
<td>Change of equipment and technique increases the likelihood of success and improves the efficiency of the procedure.</td>
</tr>
<tr>
<td>6</td>
<td>Centers and physicians performing CTO-PCI should have the necessary equipment, expertise, and experience to optimize success and minimize and manage complications.</td>
</tr>
<tr>
<td>7</td>
<td>Every effort should be made to optimize stent deployment in CTO PCI, including the frequent use of intravascular imaging.</td>
</tr>
</tbody>
</table>

CTO indicates chronic total occlusion; and PCI, percutaneous coronary intervention.
or secondary prevention had a higher risk for ventricular arrhythmias than patients with nonocclusive coronary artery disease, and a higher frequency of recurrent ventricular tachycardia after ablation; there have been no randomized studies, however, examining whether CTO-PCI reduces the risk for subsequent arrhythmias. In observational studies, patients presenting with ST-segment–elevation acute myocardial infarction and a CTO in a nonculprit coronary artery had higher risk for developing cardiogenic shock and higher mortality.

In several observational studies of successful versus failed CTO-PCI, patients with successful procedures had lower mortality than those who had unsuccessful procedures, but observational studies are subject to bias. Observational studies have also demonstrated a lower incidence of major adverse cardiac events with CTO-Occlusion; NCT03392415). With Myocardial Ischemia; NCT03563417) and the Medical Therapy of Chronic Total Coronary Occlusions (NORDIC-BALTIC Randomized Registry Study on the Effect of Revascularization or Optimal Medical Therapy of Chronic Total Coronary Occlusions With Myocardial Ischemia; NCT03563417) and the NOBLE-CTO study (Nordic-Baltic Randomized Registry Study for Evaluation of PCI in Chronic Total Coronary Occlusion; NCT03392415).

In the 2011 American College of Cardiology/American Heart Association PCI guidelines, CTO-PCI carries a class IIA/level of evidence B recommendation: “PCI of a CTO in patients with appropriate clinical indications and suitable anatomy is reasonable when performed by operators with appropriate expertise.” The 2018 European Society of Cardiology/European Association of Cardiothoracic Surgery guidelines on myocardial revascularization CTO-PCI carries a class IIA/level of evidence B recommendation: “Percutaneous recanalization of CTOs should be considered in patients with angina resistant to medical therapy or with large area of documented ischemia in the territory of the occluded vessel.” In summary, improving patient symptoms caused by myocardial ischemia (angina, exertional dyspnea, and sometimes fatigue) despite optimal medical therapy remains the only benefit of CTO-PCI that has been demonstrated in randomized, controlled trials and should therefore currently be the primary indication for offering this procedure to patients. An office-based risk/benefit conversation with prospective patients undergoing CTO-PCI is strongly encouraged to provide realistic expectations before the procedure.

**DUAL ANGIOGRAPHY AND DETAILED, STRUCTURED ANGIOGRAPHIC REVIEW**

The simplest, yet most powerful technique for improving technical success and reducing complications of CTO-PCI is the performance of high-quality, simultaneous dual coronary angiography. The use of 2 catheters and pressure-monitoring systems adds little time and cost to the procedure. Dual coronary angiography allows better visualization and understanding of CTO anatomy and is pivotal in estimating the complexity of the lesion and the likelihood of success. Moreover, it improves procedural safety by elucidating the guidewire location during crossing attempts and facilitating the management of periprocedural complications, such as perforation. CTO-PCI with a single guide can be performed in selected cases with collateral circulation exclusively coming from ipsilateral vessels, for example, in CTOs located in a left dominant system. In the latter scenario, selective contrast injection in the collateral donor branch through a microcatheter can be performed to reduce contrast administration and to avoid propagation of antegrade dissection zones. The ping-pong technique, ie, the use of 2 catheters in the left main coronary artery, will allow for easier guidewire and microcatheter management, especially when using a retrograde approach.

Before the procedure, a detailed review and analysis of the angiogram and, if available, coronary computed tomography angiography (CCTA) is essential for creating a primary and secondary procedural plan and assessing the risk/benefit ratio of the procedure. To allow adequate time for procedural planning and preparation and for proper counseling of patients, ad hoc CTO-PCI is discouraged in most cases. CTO-PCI preplanning can also help minimize contrast and radiation dose, reduce patient and operator fatigue, allow additional evaluation (such as myocardial viability) to be performed, and enable detailed discussion with the patient about all the aspects of the CTO-PCI procedure.

CTO anatomy will dictate the most likely successful and safest crossing strategies. Angiographic review of the CTO anatomy focuses on 4 characteristics (Figure 1): (1) proximal cap morphology; (2) occlusion length, course, and composition (eg, calcium); (3) quality of the distal vessel; and (4) characteristics of the collateral circulation. Moreover, non-CTO lesions are reviewed, because assessing intermediate left main or other lesions may change clinical decision making leading to alternative revascularization strategies, such as coronary artery bypass graft surgery or pre–CTO-PCI stenting of a donor artery.

**Proximal Cap Morphology**

Determining the location and morphology of the proximal cap is critical for selecting an optimal approach to...
CTO-PCI. Attempts to cross ambiguous proximal caps may lead to perforation. Additional angiographic projections using dual injection, selective contrast injection through a microcatheter located near the proximal cap, use of intravascular ultrasound, or preprocedural or real-time CCTA coregistration may help clarify the location of the proximal cap. If proximal cap ambiguity cannot be resolved, a retrograde approach is often recommended as primary strategy.

Lesion Length, Course, and Composition

Lesion length is often overestimated with antegrade-only injections because of underfilling and poor opacification of the distal vessel, from competing antegrade and retrograde coronary flow, leaving uncertainty about the location and morphology of the distal cap. Dual injection or preprocedural CCTA allows more accurate estimation of CTO length and the distal cap anatomy. Severe calcification and tortuosity of the occluded segment can hinder CTO crossing and increase the likelihood of subadventitial guidewire entry. Advancing a knuckled (J-shaped) guidewire or changing to the retrograde approach is often preferred when the vessel course is unclear or highly tortuous, because such a J-shaped or knuckled wire allows advancement within the vessel architecture with a low risk of perforation.

Distal Vessel

A distal vessel of large caliber (>2.0 mm) that fills well does not have significant disease and is free from major branches facilitates CTO recanalization. Conversely, small, diffusely diseased distal vessels are more challenging to recanalize, especially after subintimal guidewire entry. In some cases, however, distal vessels are small because of hypoperfusion, leading to negative remodeling, and will increase in size after recanalization. Distal CTO caps in native coronary artery CTOs are more likely to be calcified and resistant to guidewire penetration in patients with previous coronary artery bypass grafting. Moreover, distal vessel calcification may hinder wire reentry in case of subintimal guidewire entry.

Collateral Circulation

Evaluation of the collateral circulation is critical for determining the feasibility of the retrograde approach. High-quality angiography (ideally obtained during breath hold and without panning), allowing complete opacification of collateral vessels and obtained in optimal angiographic projections, should therefore be encouraged as part of the routine diagnostic studies when a CTO is found. Retrograde access to the distal vessel can be obtained via septal collaterals, epicardial collaterals, or (patent or occluded) coronary bypass grafts. When assessing collateral channels, it is important to consider size, tortuosity, bifurcations, angle of entry to and exit from the collateral, and distance from the collateral exit to the distal cap. The most important predictor of successful guidewire and device crossing is lack of tortuosity, followed by size. The size of the collaterals is often assessed by using the Werner classification (CC0, no continuous connection; CC1, threadlike connection; and CC2, side branch-like connection). Crossing invisible septal collateral channels is often possible with the surfing technique, letting the wire find the path of least resistance. It is helpful to carefully study previous angiograms for multiple potential collateral pathways, because the predominant collateral may change over the time before the procedure or during the course of...
PCI (shifting collaterals). Previously visualized collaterals that disappear at the time of the procedure may still be crossable. Whenever required, and after ensuring adequate backflow to prevent barotrauma, selective contrast tip injections through the microcatheter can be safely performed to outline collateral anatomy. Patient bypass grafts represent an ideal retrograde conduit because of the absence of side branches, predictable course, and large caliber. Even occluded grafts can be used as retrograde pathways. However, in case of collateral circulation originating from the left anterior descending artery, that is supplied by a mammary artery, access via the internal mammary artery graft increases the risk of global ischemia and should be avoided whenever possible.41

Septal collaterals are typically safer and easier to navigate using very soft tip and polymer-jacketed guidewires in comparison with epicardial collaterals.42,43 In contrast to epicardial collaterals, septal collaterals can be safely dilated with small balloons to facilitate microcatheter or device crossing if required. The donor vessel proximal to the collateral origin, and collateral dominance (ie, presence of a single large visible collateral), should also be assessed during retrograde procedures to determine the risk for ischemia during retrograde crossing attempts. Careful review of collaterals before the procedure can reduce contrast and radiation dose, and the duration of the procedure. In cases where the collateral anatomy is unclear or ambiguous, it can be helpful to perform selective injection of contrast into the collateral through the center lumen of a microcatheter placed into the collateral by using a 2- to 3-mL syringe. Furthermore, in cases where unfavorable noninterventional epicardial collaterals provide the dominant blood flow to the CTO, it can be useful to balloon occlude the epicardial collateral for 2 to 4 minutes to see if more favorable interventional collaterals can be recruited and identified for attempts at retrograde crossing.

CTO Scores

Angiographic and clinical characteristics, such as previous CTO-PCI failure44 and previous coronary artery bypass grafting,45 have been combined to create scores for estimating the difficulty and hazard of a specific CTO-PCI in various patient populations. The first and most commonly used CTO-PCI score is the J-CTO score (Multicenter CTO Registry of Japan), developed to estimate the likelihood of successful antegrade guidewire crossing within 30 minutes based on 5 criteria (at least 1 bend of >45° in the CTO entry or CTO body, occlusion length >20 mm, calcification, blunt proximal stump, and previously failed attempt).46 The J-CTO score has been validated in other CTO-PCI cohorts44 and is also associated with 1-year clinical outcomes.47 Other scores include the PROGRESS-CTO score,48 the RECHARGE (Registry of Crossboss and Hybrid Procedures in France, the Netherlands, Belgium and United Kingdom) registry score,49 the CL-score (Clinical and Lesion related score),50 the ORA (ostial location, collateral filling of Rentrop <2, age >75) score,51 the Ellis et al52 score, the weighted angiographic scoring model (W-CTO score),53 and the CASTLE (coronary artery bypass grafting history, age ≥70 years, stump anatomy [blunt or invisible], tortuosity degree [severe or unseen], length of occlusion [≥20 mm], and extent of calcification [severe]) score.54 There are also CCTA-based scores, such as the CT-RECTOR multicenter registry (Computed Tomography Registry of Chronic Total Occlusion Revascularization) score55 and the Korean Multicenter CTO CT Registry Score.56 Various scores have similar predictive capacity for technical success and are more accurate in antegrade-only cases.57 The risk of complications can be assessed by using the Progress-CTO complications score that uses 3 variables (age ≥65 years, lesion length ≥23 mm, and use of the retrograde approach) to stratify patients for the risk of periprocedural complications.58

In general, each score is only applicable to the population from which it was derived and validated. Calculating ≥1 scores can promote detailed review of the angiogram and facilitate decision making. For example, medical therapy may be preferred over CTO-PCI in mildly symptomatic patients with highly complex occlusions. Complex CTOs (such as those with J-CTO score ≥2) are more likely to require dissection reentry and retrograde crossing techniques and should be performed by experienced operators.

USE OF A MICROCATHETER FOR GUIDEWIRE MANIPULATION

A microcatheter should be routinely used for supporting the coronary guidewire and allowing rapid guidewire switching during both antegrade and retrograde wire manipulation. Microcatheters improve the precision of both rotational and longitudinal guidewire movements both in fluid (blood-filled vessels) and in tissue (the occlusion itself) and allow the penetration force of the wire to be dynamically altered by changing the distance between the tip of the guidewire and the microcatheter, with guidewires becoming stiffer when the microcatheter is positioned close to the guidewire tip. Microcatheters also allow rapid guidewire tip reshaping or exchange, while preserving previous guidewire crossing or advancement achieved. Microcatheters inherently dilate retrograde collateral channels and protect them from wire-induced trauma. Microcatheters can also be used to deliver contrast either for visualization or to accomplish the Carlin technique (intraslesional injection of 1–2 mL of contrast to elucidate microcatheter posi-
tion and facilitate crossing), especially in wire-resistant lesions.59 A microcatheter is preferred over an over-the-wire balloon because it has a marker at the distal tip, providing adequate fluoroscopic feedback of its actual position and also providing greater freedom of advancement with a lower profile and better wire-to-lumen internal diameter ratio. Also, unlike over-the-wire plastic balloon catheter shafts that are prone to kinking, nearly all contemporary coronary microcatheters incorporate a kink-resistant metallic braid.

Similar to guidewires, microcatheter selection depends on the CTO angiographic characteristics, local availability, and expertise. In addition to using a microcatheter, obtaining coaxial guide position and strong guide support can significantly facilitate CTO crossing.

**CTO CROSSING STRATEGIES**

There are 4 CTO crossing strategies, classified according to wiring direction (antegrade and retrograde) and whether or not the subintimal space is used (wiring versus dissection and reentry; Figure 2).29,30

**Antegrade Wiring**

Antegrade wiring (also called antegrade wire escalation) is the most widely used CTO crossing technique.31,60–62 Various guidewires are advanced in the antegrade direction (original direction of blood flow). Guidewire choice depends on CTO characteristics. If there is a tapered proximal cap or a functional occlusion with a visible channel, a polymer-jacketed, low penetration force, tapered guidewire is used initially, with subsequent escalation to intermediate and high penetration force guidewires, as required. If there is a blunt proximal cap, antegrade wiring is usually started with an intermediate penetration force polymer-jacketed guidewire, or a composite core guidewire. Stiff, high penetration force guidewires may be required in highly resistant proximal caps or when areas of resistance are encountered within the body of the occlusion. After proximal cap crossing of 1 to 2 mm, however, deescalation to less penetrating guidewires should follow to navigate through the CTO segment.

Contralateral injection and orthogonal angiographic projections are critical for determining guidewire position during crossing attempts. If the guidewire enters into the distal true lumen, the microcatheter is then advanced into the distal true lumen, and the dedicated CTO guidewire is then exchanged for a workhorse guidewire through the microcatheter to minimize the risk for distal vessel injury and perforation during balloon angioplasty and stenting (wire deescalation). If the guidewire exits the vessel structure, it should be withdrawn and redirected without advancing microcatheters, balloons, or stents over it. If the guidewire enters the subintimal space, it can be redirected, but if this maneuver fails, the wire can be left in place to aid directing a second guidewire into the distal true lumen (parallel-wire technique), which can be assisted by a dual-lumen microcatheter or facilitated by the use of intravascular ultrasound.31 Alternatively, antegrade dissection/reentry techniques can be used to reenter into the distal true lumen, as described below. Subintimal guidewire advancement distal to the distal cap should be avoided because it can lead to hematoma formation, causing luminal compression and reducing the likelihood of success. Antegrade vessel reentry can be guided by intravascular ultrasound, although this approach requires expertise and may be hindered by limited wire maneuverability in the presence of the subintimal intravascular ultrasound catheter.

**Antegrade Dissection and Reentry**

Antegrade dissection and reentry involves entering the subintimal space, followed by subintimal crossing of the CTO with subsequent reentry into the distal true lumen. Antegrade dissection and reentry may be intentional or unintentional during antegrade wiring attempts. The first developed dissection reentry technique was named STAR (Subintimal Tracking And Re-Entry) and used inadvertent, uncontrollable reentry into the distal lumen.63 This frequently necessitated stenting long coronary segments with occlusion of numerous side branches, leading to extensive vascular injury and high rates of in-stent restenosis and reocclusion.63–65 As such, the STAR technique has evolved to a bailout strategy without stent implantation after ballooning, in preparation for a repeat CTO-PCI attempt (subintimal plaque modification, also termed an “investment procedure”)66–68 The development of limited dissection/reentry techniques (using dedicated reentry systems69,70 or wire-based strategies71) was an important advancement, because they minimize vascular injury, limit the length of dissection and subsequent stent length, and increase the likelihood of side branch preservation.69,70,72 Such approaches have been associated with favorable clinical outcomes.72–76

**Retrograde Approach**

The retrograde technique differs from the antegrade approach in that the occlusion is approached from the distal vessel with guidewire advancement against the original direction of blood flow.77 A guidewire is advanced into the artery distal to the occlusion through a collateral channel or through a bypass graft, followed by placement of a microcatheter at the distal CTO cap. Retrograde CTO crossing is then attempted either with retrograde wiring (usually for short occlusions, especially when the distal cap is tapered79) or using retrograde dissection/reentry techniques.
The most commonly used retrograde crossing technique is reverse controlled antegrade and retrograde tracking, in which a balloon is inflated over the antegrade guidewire, followed by retrograde guidewire advancement into the space created by the antegrade balloon (Figure 2). In challenging reverse controlled antegrade and retrograde tracking cases, intravascular ultrasound can clarify the mechanism of failure and increase the likelihood of success. Guide catheter extensions can also facilitate reverse controlled antegrade and retrograde tracking.

Crossing Strategy Selection
Selecting the initial and subsequent crossing strategies depends on the CTO lesion characteristics and local equipment availability and expertise.

Several algorithms have been developed to facilitate crossing strategy selection, such as the hybrid algorithm, Asia Pacific, and Euro-CTO algorithms. Antegrade crossing is generally preferred over retrograde crossing as the initial crossing strategy, given the higher risk of complications with the retrograde approach and the need for antegrade lesion preparation even when the retrograde approach is eventually required. Some retrograde CTO-PCI complications, however, are caused by antegrade crossing attempts. The retrograde approach remains critical for achieving high success rates, especially in more complex CTOs, and has been associated with favorable long-term outcomes. CTOs with proximal cap ambiguity and flush aortoostial CTOs are often approached with a primary retrograde strategy. Alternatively, proximal cap ambiguity can be approached in the antegrade direction, especially when no collateral or graft is available by using (1) intravascular ultrasound or preprocedural CCTA for determining the location of the proximal cap and vessel course, or (2) techniques to facilitate entry into
the subintimal space proximal to the occlusion, such as the balloon-assisted subintimal entry (ie, inflation of a balloon proximal to the occlusion to cause a dissection, followed by subintimal guidewire entry and subintimal crossing of the occlusion) technique.64

**CHANGE OF CROSSING STRATEGY**

Flexibility is important for the success, safety, and efficiency of CTO-PCI. If the initial or subsequent crossing strategy fails to achieve progress, small changes (such as modifying the guidewire tip angulation or changing guidewire) or more significant changes (such as converting from an antegrade to a retrograde approach) should be made, based on preprocedural planning.29,35 It is important to avoid getting stuck in a failure mode, in which excessive time, radiation, and contrast are expended with little or no progress being made while repeatedly attempting the same technique, because this will preclude the use of alternative strategies and increase the risk of complications.

Similar to selection of the initial crossing strategy, the timing and choice of subsequent crossing strategies depends on lesion characteristics, challenges encountered with the original technique, and equipment availability and expertise, and can be guided by existing crossing algorithms.29,35 Only ≈50% to 60% of CTOs are successfully crossed with the initial strategy,28,60,61 highlighting the need for further refinements in the procedure-planning algorithms. Changing strategies can help maximize the likelihood of eventual success and limit contrast volume and radiation dose.

Reasons to stop a CTO-PCI attempt include occurrence of a complication, high radiation dose (usually >5 Gy air kerma dose in the absence of lesion cross-}
the risk of donor vessel thrombosis; the activated clotting time should be checked at least every 30 minutes during the procedure. In case of perforation, covered stents and coils should be available to treat large vessel and distal vessel perforations, respectively. Preprocedural operator training in the proper use of these devices will ensure efficient use in the emergency setting. In case of epicardial collateral perforation, embolization from both directions (using coils, thrombin, fat, etc) is often needed to achieve sealing. Special attention should be given to patients with previous coronary bypass graft surgery, because perforation can result in life-threatening, difficult to access, loculated hematomas or bleeding in the mediastinum or pleural cavities.

Meticulous attention should also be paid to minimizing radiation dose and the risk for radiation skin injury. This can be achieved by using low-frame rate fluoroscopy and the fluoroscopy-store function for documenting balloon and stent inflation instead of cine-angiography, using collimation, minimizing the distance of the image receptor from the patient, and intermittently changing the position of the image receptor during the procedure. Patients who receive high doses of radiation (eg, >5 Gray air kerma dose) require formal follow-up to evaluate for subacute skin injury. Similarly, contrast administration should be minimized through meticulous preprocedural planning and use of contrast-sparring devices to reduce the risk for contrast nephropathy.

**OPTIMAL STENT DEPLOYMENT**

CTO-PCI often involves placement of multiple stents in vessels that are calcified, diffusely diseased, and negatively remodeled. Given the often arduous and lengthy attempts required for CTO crossing, less attention may be given to stent optimization (maximal stent expansion and optimal inflow and outflow), potentially resulting in higher rates of restenosis and stent thrombosis. Full lesion expansion should be achieved before stent implantation by predilation with properly sized balloon or atherectomy. Intravascular imaging can facilitate the assessment of vessel size and calcification before stenting and the adequacy of stent expansion, apposition and lesion coverage, to reduce the risk for subsequent adverse events. Moderate diffuse disease distal to the CTO often does not require treatment, because the distal vessel often enlarges over time after restoring vessel patency.

**CONCLUSIONS**

Extensive interactions and collaboration across the world have led to the advancements in CTO-PCI that are summarized in the 7 key principles outlined in this global expert consensus document. These principles can guide training of new CTO-PCI operators and program development and facilitate further improvement in the success, safety, and clinical outcomes of CTO-PCI.

**ARTICLE INFORMATION**

**Authors**
Emmanuelou S. Brilakis, MD, PhD; Karnbis Mashayekhi, MD; Etsuo Tsuchikane, MD, PhD; Nidal Abi Rafeh, MD; Khaldoon Alaswad, MD; Mario Araya, MD; Alexandre Avaran, MD; Lorenzo Azzalini, MD, PhD, MSc; Avandil M. Babunashvili, MD; Baktash Bayani, MD; Rvinay Bhandi, MD; Nicolas Boudou, MD; Marouane Boukhri, MD; Renaz Gouda, MD; Leszek Bryniarski, MD, PhD; Alexander Bufe, MD; Christopher E. Buller, MD; M. Nicholas Burke, MD; Heinz Joachim Büttner, MD; Pedro Cardoso, MD; Mauro Carlino, MD; Evald H. Christiansen, MD; Antonio Colombo, MD; Kevin Croce, MD, PhD; Felix Damas de los Santos, MD; Tony De Martini, MD; Joseph Denis, MD, PhD; Carlo Di Mario, MD; Kefei Dou, MD; Mohamed Egered, MD; Ahmed M. ElGindy, MD; Javier Escaned, MD, PhD; Antonio Furlko, MD; Andrea Gagnon, MD; Alfredo R. Galassi, MD; Roberto Garbo, MD; Junbo Ge, MD; Pravin Kumar Goel, MD; Omer Gokekten, MD; Luca Grancini, MD; J. Aaron Grantham, Colm Hanratty, MD; Stefan Harb, MD; Scott A. Harding, MD; Jose P.S. Henriques, MD; Jonathan M. Hill, MD; Farouc A. Jaffer, MD, PhD; Yangsoo Jung, MD; Risto Jussila, MD; Artis Kalnins, MD; Arun Kalyanasundaram, MD; David E. Kandzari, MD; Hsien-Li Kao, MD; Dimitri Karmpaliotis, MD, PhD; Hussein Heshmat Kassem, MD, PhD; Paul Knaapen, MD; Ran Kornowiski, MD; Oleg Krestyaninov, MD; A. V. Ganesh Kumar, MD; Peep Laanemets, MD; Pablo Lamelas, MD; Seung-Whan Lee, MD; Thierry Lefevre, MD; Yue Li, MD; Soo-Teik Lim, MD; Sidney Lo, MBBS; William Lombardi, MD; Margaret McIntegart, MD, PhD; Muhammad Munawar, MD; José Andrés Navarro Lecaro, MD; Hung M. Ngo, MD, PhD; William Nicholson, MD; Góran K. Olivecrona, MD, PhD; Lucio Padilla, MD; Marin Postu, MD; Alexandre Quadrinos, MD, PhD; Frankin Hanna Queasad, MD; Vithala Surya Prakash Rao, MD; Nicolas Reiffert, MD; Meruzaimeh Saghatelayan, MD; Ricardo Santiago, MD; George Sianos, MD, PhD; Elliot Smith, MD; James C. Spratt, MD; Gregg W. Stone, MD; Julian W. Strange, MD; Khalid Tamamm, MD, PhD; Imre Ungi, MD, PhD; Minh Vo, MD; Vu Hoang Vu, MD; Simon Walsh, MD; Gerald S. Werner, MD; Jason R. Wollmuth, MD; Eugene B. Wu, MD; R. Michael Wyman, MD; Bo Xu, MD; Masahisa Yamane, MD; Luiz F. Ybarra, MD; Robert W. Yeh, MD; Qi Zhang, MD; Stephane Rinfret, MD, SM

**Correspondence**
Emmanuelou S. Brilakis, MD, PhD, Minneapolis Heart Institute, 920 E 28th St #300, Minneapolis, MN 55407. Email esbrilakis@gmail.com

**Affiliations**
Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, MN (E.S.B., M.N.B.). Department of Cardiology and Angiography II University Heart Center Freiburg Bad Krozingen, Germany (K.M., H.J.B.). Toyohashi Heart Center, Aichi, Japan (E.T.). St. George Hospital University Heart Centre Freiburg Bad Krozingen, Germany (K.M., H.J.B.). Arnault Tzank Institut St. Laurent Du Var Nice, France (A.A.). Interventional Cardiology Division, Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy (L.A., M.C.). Department of Cardiovascular Surgery, Center for Endorsurgery and Lithotripsy, Moscow, Russian Federation (A.M.B.). Cardiology Department, Mehr Hospital, Mashhad, Iran (B.B.). Department of Cardiology, Royal North Shore Hospital and Kolling Institute, University of Sydney, Australia (R.B.). Rangueil University Hospital, Toulouse, France (N.B.). Cardiology department, Abergavenny Mari Hospital, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunisia (M.B.). Department of Interventional Cardiology Clinic for Cardiovascular Diseases University Clinical Center Nis, Serbia (N.Z.B.). II Department of Cardiology and Cardiovascular Interventions Institute of Cardiology, Jagiellonian University Medical College, Cracow, Poland (L.B.). Department of Cardiology, Heartcentre Niederrhein, Helios Clinic Krefeld, Krefeld, Germany, Institute for Heart and Circulation Research, University of Cologne, Germany, and University of Witten/Herdecke, Witten, Germany (A.B.). St. Michael's Hospital, Toronto, ON, Canada (C.E.B.). Cardiology Department, Santa Maria University Hospital (CHULN), Lisbon Academic Medical Centre (CAML) and Centro Cardiovascular da Universidade de Lisboa (CCUL), Por-

428 July 30, 2019

Circulation. 2019;140:420–433. DOI: 10.1161/CIRCULATIONAHA.119.039797
Department. Department of Cardiology, Aarhus University Hospital, Denmark (E.H.C.). San Rafaele Hospital and Columbus Hospital, Milan, Italy (A.C.). Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA (K.C.). Interventricular Cardiology Department, Instituto Nazionale di Cardiologia Ignazio Châvez Mexico City, Mexico (F.D.d.l.S.). SIU School of Medicine, Memorial Medical Center, Springfield, IL (T.D.M.). Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium (J.D.). Structural Interventional Cardiology, Cardarelli University Hospital, Florence, Italy (C.D.M.). Center for Coronary Heart Disease, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, and National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing (K.D.). Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom (M.E.E.). Department of Cardiology, Aswan Heart Center, Egypt (A.M.E.). National Heart and Lung Institute, Imperial College London, United Kingdom (A.M.E.). Hospital Clinico San Carlos IDISSC and Universidad Complutense de Madrid, Spain (F.A.J.). Department of Endovascular Surgery and Angiography, National Institute of Surgery and Transplantology of AMS of Ukraine, Kiev (S.F.). Department of Invasive Cardiology, Maria Vittoria Hospital, Turin, Italy (A.G.). Chair of Cardiology, Department of PROMISE, University of Palermo, Italy (A.R.G.). Director of Interventional Cardiology, San Giovanni Bosco Hospital, Turin, Italy (R.G.). Zhongshan Hospital, Fudan University, Shanghai, China (J.G.). Sanjay Gandhi Post Graduate Institute of Medical Sciences Lucknow, India (P.K.G.). Memorial Hospital, Istanbula (J.K.). Centro Cardiologico Monzino, IRCCS, Milan, Italy (L.G.). Saint Luke’s Mid America Heart Institute, Kansas City, MO (J.A.O.). Belfast Health and Social Care Trust, United Kingdom (C.H., S.W.). LHK Graz II, Standort West, Kardiologie, Teaching Hospital of the University of Graz, Austria (S.H.). Wellington Hospital, Capital and Coast District Health Board, New Zealand (S.A.H.). Academic Medical Centre of the University of Amsterdam, The Netherlands (J.F.S.H.). King’s College Hospital, London, United Kingdom (J.M.H.). Cardiovascular Diagnostics and Therapeutics, Instituto Cardiovascular of Madrid, Spain (E.A.). Cardiovascular Division, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, South Korea (Y.J.H.). Helsinki Heart Hospital, Finland (R.J.). Department of Cardiology, Eastern Clinical University Hospital, Riga, Latvia (A. Kalnis). Promed Hospital, Chenghai, India (A. Kalyanasundaram). Piedmont Heart Institute, Atlanta, GA (D.E.K.). Department of Internal Medicine, National Taiwan University Hospital, Taipei (H.-L.K.). Columbia University, New York (D.C.). University Hospital, Karolinska Almedalen, Sweden, Sweden (J.M.H.). Cardiovascular Diseases “Prof. Dr. C.C. Iliescu,” Bucharest, Romania (M.P.). Clinica Cardiovascular y Angioplastia de Madrid, Spain (J.M.H.). Cardiovascular Intervention, Instituto Cardiovascular de Buenos Aires, Argentina (P. Lamelas). Department of Research Health Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada (D. Lamelas). Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (S.-W.L.). Instituts Cardiovasculaire Paris Sud Hospital prive Jacques Cartier, Massy, France (T.L.). Department of Cardiology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China (Z.G.). National Institute of Cardiovascular, National Heart Centre Singapore (S.-T.L.). Department of Cardiology, Liverpool Hospital and The University of New South Wales, Sydney, Australia (S.L.). University of Washington, Seattle (W.L.). Golden Jubilee National Hospital, Glasgow, United Kingdom (M. McEnteggart). Binauralya Cardio Center, Jakarta, Indonesia (M. Munawar). Medico Cardiologo Universitario - Hemodinamist in hospita de Especialidades Eugenio Espejo y Hospital de los Valles, Ecuador (J.A.N.L.). Choray Hospital, Vietnam (H.M.N.). WellSpan Health System, York, PA (W.N.). Skane University Hospital, University of Lund, Sweden (G.K.O.). Department of Interventional Cardiology and Endovascular Therapeutics, Instituto Cardiovascular de Buenos Aires, Argentina (P. Lamelas). Department of Research Health Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada (D. Lamelas). Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (S.-W.L.). Instituts Cardiovasculaire Paris Sud Hospital prive Jacques Cartier, Massy, France (T.L.). Department of Cardiology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China (Z.G.). National Institute of Cardiovascular, National Heart Centre Singapore (S.-T.L.). Department of Cardiology, Liverpool Hospital and The University of New South Wales, Sydney, Australia (S.L.). University of Washington, Seattle (W.L.). Golden Jubilee National Hospital, Glasgow, United Kingdom (M. McEnteggart). Binauralya Cardio Center, Jakarta, Indonesia (M. Munawar). Medico Cardiologo Universitario - Hemodinamist in hospita de Especialidades Eugenio Espejo y Hospital de los Valles, Ecuador (J.A.N.L.). Choray Hospital, Vietnam (H.M.N.). WellSpan Health System, York, PA (W.N.). Skane University Hospital, University of Lund, Sweden (G.K.O.). Department of Interventional Cardiology and Endovascular Therapeutics, ICBA, Instituto Cardiovascular, Buenos Aires, Argentina (L.P.). Cardiology Department, University of Medicine and Pharmacy “Carol Davila,” University of Cardiovascular Diseases “Prof. Dr. C. C. Ilesuc,” Bucharest, Romania (M.P.). Instituto de Cardiologia / Fundação Universidade de Cardiologia – IFCUF, Porto Alegre, RS – Brazil (A.O.). Interventional Cardiology Department, Clinica Com- paredre Pereira City, Colombia (F.H.O.). Hygudarpa Apollo, Hyderabad, India (V.S.P.R.). Department of Cardiology, Main Taurus Heart Institute, Bad Soden, Germany (N.R.). Nork-Marash Medical Center, Yerevan, Armenia (M.S.). Hospital Pavia Santiturce, PCI Cardiology Group, San Juan, Puerto Rico (R.S.T.). AHEPA University Hospital, Thessaloniki, Greece (G.S.). Department of Cardiology, Barts Heart Centre, St Bartholomew’s Hospital, London, United Kingdom (E.S.). St. Gallican Cardiovascular Centre, Royal Leamington NJS Trust, Leamington Spa, United Kingdom (E.S.). Department of Interventional Vascular Therapy, Division of Cardiology, New York-Pres- eylerian Hospital/Columbia University Medical Center (G.S.). Department of Cardiology, Bristol Royal Infirmary, United Kingdom (J.W.S.). Cardiac Center of Excellence, International Medical Center, Jeddah, Saudi Arabia (K.T.). Department of Internal Medicine and Cardiology Center, University of Szeged, Hungary (I.U.). Mazankowski Alberta Heart Institute, Edmonton, AB, Canada (M.V.). Interventional Cardiology Department, Heart Center, University Medical Center at Ho Chi Minh City, and University of Medicine and Pharmacy, Vietnam (H.V.). Medizinische Klinik I Klinikum Darmstadt GmbH, Germany (G.W.). Provi- dence Heart Institute and VA Portland, OR (J.R.W.). Prince of Wales Hospi- tal, Hong Kong (E.W.). Torrance Memorial Medical Center, CA (R.M.W.). Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing (B.X.). Satimta St. Luke’s International Hospital, Tokyo, Japan (M.Y.). London Health Sciences Centre, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada (L.F.Y.). Beth Israel Dea- coness Medical Center, Boston, MA (R.W.Y.). Shanghai East Hospital, Tongji University, China (Z.Q.). McGill University Health Centre, McGill University, Montreal, QC, Canada (S.R.).

Acknowledgment

We recognize the assistance of Dr IoSof Xenogiannis in the creation of this document.

Disclosures


Dr Kalyanasundaram: Speaker, consultant, and proctor for Boston Scientific, Asahi, and Abbott Vascular. Dr Kandzari: Research/grant support to Medtronic, Boston Scientific, Biotronik; consulting honoraria: Medtronic, Boston Scien- tific, Biotronik, and CSI. Dr Kao: Speaker/proctor honoraria: Abbott Vascular, Asahi Intec, Biotronik, Boston Scientific, Medtronic, Orbus Neich, and Terumo. Dr Korteweg: Honorary, speaker, and proctor for Medtronic and United Kin. Dr Kornowski: Co-founder of NitLoop. Dr Krestyaninov: Speaker and proctor honoraria from Abbott Vascular. Dr Laamets: Consultant for Terumo. Dr Lee:

REFERENCES


